USRM going to sub .019. There’s no young blood in this company.
USRM has relied on their research but has failed to adapt to the market, which is why they started selling training and ‘regenerative products’. The procedures they train... well there’s a lot of training companies doing the same. Additionally there’s even evidence showing that the rejection rate of donor cells is conflicted and actually low. In fact in certain scenarios an Autogolos procedure is less beneficial.
With 500k in capital I could bring a functioning product for allogeneic cells making the same day procedure in adequate, and no training required on extraction but only on administration of the cells.
Stem cells will continue to play a role in medicine in an decentralized manner, where clinicians can perform the procedure similar to other procedures. THE only thing USRM has is the research they’ve done. But allogeniec cells are proving to be beneficial.
My theoretical company will be a provider of allo-MSC cells and thus have something tangible to distribute. But to get in the game of being a clinic to provide a more risky procedure of auto-MSC administration could be where USRM is headed along with an influx of physicians performing the procedure, so there is no market advantage USRM has... other than their claim to research. But they can’t monetize the research, which is why other clinicians are now doing the procedure and nobody has to pay 2 cents to USRM, even though USRM has the longest record of dealing in this market. USRM has no market advantage with their procedures, and no tangible product to distribute. Regenerative products may be effective to an extent but without being covered by insurance who will really buy these products? And let’s say you do all the USRM products and pay 100k, are you going to walk away with new hair? Maybe you will but why not go to another regenerative medicine clinic?
USRM needs to work a tangible device, product or service into medical protocols in order to gain market advantage.. for example a device specifically made to fit in a cast, like a valve,
and after each cast is applied it allows you to inject cells through the cast... this patented pending device is then worked into the procedure of every cast and is insurable cause it’s the only one approved. The founder of USRM who is 97 is known for making medical devices and could fit this in. But yes more clinical trials will remain.
But you get the idea of where this market is, and how to capitalize? The myocatheter was a great idea and well if something like that doesn’t get in play... these regenerative medicine products are just anything mom and pop could be selling on the Vegas strip for hungover tourists... (btw there is a NAD injection clinic in one of the lobbies as we speak, and oxygen bars are not new)
AI
